Inmune Bio Inc Stock Price, News & Analysis

INmune Bio has secured a $2.9 million Small Business Innovation Research (SBIR) grant from the NIH to support a Phase 2 study of XPro1595, a treatment for treatment-resistant depression (TRD). This randomized, blinded study will involve 100 patients and utilize neuroimaging to explore neuroinflammation's role in TRD. With the study's sites at Emory University and the University of Alabama, the funding will be distributed over the next three years. The findings could have significant implications for treating TRD and related neurodegenerative diseases.

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology firm, will participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit on September 23, 2020. The management team is open for virtual one-on-one meetings during the event. Interested parties can schedule meetings through a conference representative or contact James Carbonara at James@haydenir.com. The company focuses on harnessing the innate immune system to develop treatments for various diseases, including COVID-19 and cancer.

INmune Bio (NASDAQ: INMB) announced that the European Patent Office has granted a patent for XPro1595, an innovative treatment for neurological disorders, including Alzheimer’s Disease. The patent, effective until 2033 and owned by Xencor, Inc., highlights XPro1595's ability to cross the blood-brain barrier, allowing less invasive peripheral administration. Clinical data suggest a 40.6% reduction in neuroinflammation in key brain regions in Alzheimer’s patients. This patent positions INmune Bio to enhance its development efforts in the European market for CNS disorders.

INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for August 5, 2020, at 4:30 PM ET to discuss Q2 results for the period ending June 30, 2020. The call aims to provide insights into the company’s ongoing development of treatments targeting the innate immune system, which includes products under the DN-TNF platform and the Natural Killer Cell Priming Platform. These platforms are designed to combat various diseases including COVID-19 complications, cancer, Alzheimer's, and chronic inflammation.

INmune Bio, Inc. (NASDAQ: INMB) was featured on Fox Business News, with CEO Dr. Raymond Tesi discussing the company's planned phase two human trials for a potential COVID-19 treatment using an anti-inflammatory drug. The segment highlighted the company's focus on leveraging the patient’s innate immune system and addressing lower drug costs. INmune Bio is developing several treatments through its DN-TNF and Natural Killer Cell Priming platforms, targeting diseases such as cancer, Alzheimer's, and COVID-19 complications.

INmune Bio, Inc. (NASDAQ: INMB) announced the completion of its public offering, raising approximately $23.1 million by issuing 2,500,000 shares at $10.00 per share. The offering included 2,173,914 shares and an additional 326,086 shares sold under the underwriters' option. The proceeds are intended for general corporate purposes, specifically research and development, including clinical trials. The offering was conducted under a shelf registration statement effective since April 2020.

INmune Bio, Inc. (NASDAQ: INMB) announced pricing for its underwritten public offering of 2,173,914 shares at $10.00 each, potentially raising approximately $21.7 million before expenses. An additional 326,086 shares may be purchased by underwriters. The offering is anticipated to close by July 20, 2020. The net proceeds of around $20 million will support general corporate needs, especially research and clinical trials for their product platforms targeting immune system-related diseases.

INmune Bio, a clinical-stage biotechnology company, has announced an underwritten public offering of common stock, subject to market conditions. The offering includes a 15% over-allotment option for underwriters. Proceeds will be used for working capital, corporate purposes, and to advance the company’s product candidates. The offering will utilize an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or buy securities in any jurisdiction where it would be unlawful.